Zobrazeno 1 - 10
of 422
pro vyhledávání: '"D Osoba"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Osoba
Publikováno v:
Neuro-Oncology. 2:221-228
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::898de7cc5d71b3bea1e0aaf4056adb2b
https://doi.org/10.1215/15228517-2-4-221
https://doi.org/10.1215/15228517-2-4-221
Autor:
K. Bennett, Maureen E. Trudeau, K. James, Jean Latreille, T. Vandenberg, Kathleen I. Pritchard, Paul E. Goss, Wycliffe S. Lofters, Susan Marlin, Rudinskas L, J. Myles, A. Rodgers, B. Findlay, J. Skillings, B. Norris, D Osoba
Publikováno v:
Journal of Clinical Oncology. 18:2385-2394
PURPOSE: This phase III study was performed to determine the superiority of doxorubicin (DOX) and vinorelbine (VNB) (arm 1) versus DOX alone (arm 2) in metastatic breast cancer (MBC) for overall survival (OS), time to treatment failure (TTF), toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0582f1b4cec4351c56d9436cd029de4c
https://doi.org/10.1200/jco.2000.18.12.2385
https://doi.org/10.1200/jco.2000.18.12.2385
Publikováno v:
Supportive Care in Cancer. 2:161-166
A number of prognostic factors have been reported to influence the probability of developing nausea and vomiting after cytotoxic chemotherapy. This study used data collected in four randomized anti-emetic trials conducted by the Clinical Trials Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4019564849ed250e73047c976ebaa84d
https://doi.org/10.1007/bf00417474
https://doi.org/10.1007/bf00417474
Autor:
D, Osoba
Publikováno v:
Canadian Medical Association journal. 80(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a247c589c89c2ba455f778ca9cb4a988
https://pubmed.ncbi.nlm.nih.gov/20325848
https://pubmed.ncbi.nlm.nih.gov/20325848
Autor:
D. Osoba
Publikováno v:
Quality of Life Research. 1:211-218
The Quality of Life Committee of the National Cancer Institute of Canada Clinical Trials Group has successfully advocated the adoption of quality of life outcomes in Canadian clinical trials in patients with cancer. It has developed a policy promotin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56507c4bc65a6fe7592d987701854978
https://doi.org/10.1007/bf00635620
https://doi.org/10.1007/bf00635620
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 14(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b7729a485b6531aeff4dc458eb71ba9
https://pubmed.ncbi.nlm.nih.gov/12206647
https://pubmed.ncbi.nlm.nih.gov/12206647
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 9(8)
Health-related quality of life (HRQL) outcomes evaluation is becoming an important component of clinical trials of new pharmaceuticals and medical devices. HRQL research provides patients, providers, and decision makers with important information on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43ce86fc0d0c0fdccbbada285efbe14b
https://pubmed.ncbi.nlm.nih.gov/11284208
https://pubmed.ncbi.nlm.nih.gov/11284208
Autor:
D Osoba
Publikováno v:
European journal of cancer (Oxford, England : 1990). 35(11)
The measurement of health-related quality of life (HRQL) in oncology clinical trials has come of age. Most cooperative clinical trials groups as well as individual institutions have either been measuring, or are starting to measure, HRQL. Over the pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd74df16a103070a68174dadf3b6d597
https://pubmed.ncbi.nlm.nih.gov/10673963
https://pubmed.ncbi.nlm.nih.gov/10673963
Autor:
D, Osoba, M, Burchmore
Publikováno v:
Seminars in oncology. 26(4 Suppl 12)
The measurement of health-related quality of life (HRQL) was an important component of clinical trials of trastuzumab (Herceptin; Genentech, San Francisco, CA) in women with progressive HER2-overexpressing metastatic breast cancer who may or may not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3ef5ad9322f1bd629c41163339b65b63
https://pubmed.ncbi.nlm.nih.gov/10482198
https://pubmed.ncbi.nlm.nih.gov/10482198